Payment overview · 2025
General Payments
$569.20
13 reported records · 9 companies
Healthcare provider profile · identity verified
Susan Jacob, MD
Allopathic & Osteopathic Physicians|Family Medicine · ZIONSVILLE, IN · NPI 1508951872
Verified facts
What the public records show
CMS Open Payments records show Susan Jacob, MD received $569.20 in general payments during 2025 across 13 reported records.
GlaxoSmithKline, LLC. accounted for 42.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $242.03 | 42.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $137.30 | 24.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.30 | 9.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.42 | 6.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.31 | 3.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.87 | 3.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.37 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.90 | 3.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.70 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $569.20 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $137.30 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $121.18 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $120.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.41 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 360 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 313 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 69 |
| Valsartan | Valsartan | 167 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 35 |
| Simvastatin | Simvastatin | 120 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 30 |
| Bupropion Xl | Bupropion Hcl | 108 | 31 |
| Omeprazole | Omeprazole | 107 | 32 |
| Losartan Potassium | Losartan Potassium | 105 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 29 |
| Trazodone Hcl | Trazodone Hcl | 91 | 27 |
| Gabapentin | Gabapentin | 90 | 34 |
| Metformin Hcl | Metformin Hcl | 88 | 24 |
| Alendronate Sodium | Alendronate Sodium | 87 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 28 |
| Eliquis | Apixaban | 82 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 26 |
| Furosemide | Furosemide | 79 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 20 |
| Montelukast Sodium | Montelukast Sodium | 69 | 23 |
| Sertraline Hcl | Sertraline Hcl | 69 | 20 |
| Allopurinol | Allopurinol | 67 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 21 |
| Tramadol Hcl | Tramadol Hcl | 66 | 21 |
| Synthroid | Levothyroxine Sodium | 65 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 63 | 14 |
| Carvedilol | Carvedilol | 62 | 14 |
| Jardiance | Empagliflozin | 61 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 16 |
| Lisinopril | Lisinopril | 58 | 20 |
| Famotidine | Famotidine | 57 | 19 |
| Spironolactone | Spironolactone | 56 | 18 |
| Irbesartan | Irbesartan | 49 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 11 |
| Metformin Hcl Er | Metformin Hcl | 46 | 13 |
| Ozempic | Semaglutide | 46 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 15 |
| Estradiol | Estradiol | 42 | 12 |
| Meloxicam | Meloxicam | 41 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 40 | 11 |
| Potassium Chloride | Potassium Chloride | 40 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 12 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 27 |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 16 |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 19 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | 13 |
| Lorazepam | Lorazepam | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 14 |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Cephalexin | Cephalexin | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $569.20 · 13 records | GlaxoSmithKline, LLC. | AREXVY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, GEMTESA, Korlym, Nubeqa, PROCLAIM, QULIPTA, SHINGRIX, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error